[HTML][HTML] Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy
OH Iwenofu, RD Lackman, AP Staddon, DG Goodwin… - Modern pathology, 2008 - Elsevier
Metastatic sarcomas are commonly resistant to chemotherapy. The serine/threonine kinase,
mammalian target of rapamycin (mTOR), is a protein kinase of the phosphatidylinositol 3-
kinase (PI3K)/AKT signaling pathway thought to have a key role in controlling cancer growth
and thus is an important target for cancer therapy. Several inhibitors of mTOR are in clinical
trials, including AP23573, which is being tested on metastatic sarcomas and other tumors.
We hypothesized that a marker for the activity of mTOR, phosphorylated S6 ribosomal …
mammalian target of rapamycin (mTOR), is a protein kinase of the phosphatidylinositol 3-
kinase (PI3K)/AKT signaling pathway thought to have a key role in controlling cancer growth
and thus is an important target for cancer therapy. Several inhibitors of mTOR are in clinical
trials, including AP23573, which is being tested on metastatic sarcomas and other tumors.
We hypothesized that a marker for the activity of mTOR, phosphorylated S6 ribosomal …